Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 3 GMAB Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
May 2 GMAB Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript
May 2 GMAB Genmab A/S 2024 Q1 - Results - Earnings Call Presentation
May 2 GMAB Genmab reports Q1 results
May 2 GMAB Genmab Announces Financial Results for the First Quarter of 2024
May 2 ALPN Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
May 1 GMAB Genmab Q1 2024 Earnings Preview
May 1 GMAB Genmab: A Complicated Tale
May 1 SLS Sellas reports positive Phase 2 data from AML study, files for patent
May 1 SLS SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
May 1 GMAB Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
May 1 TLSI TriSalus Life Sciences secures ~$50M of debt financing with OrbiMed
Apr 30 TLSI TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
Apr 30 GMAB Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Apr 30 GMAB Pfizer, Genmab cervical cancer therapy wins full FDA approval
Apr 29 GMAB FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
Apr 29 GMAB TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Apr 29 SLS SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL phase 3 study without modifications
Apr 29 SLS SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags